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ORIGINAL ARTICLE
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ABSTRACT
Objective: The treatment strategy in the very elderly with NSTE-ACS is debated, as they are often
under-represented in clinical trials. The aim of this multicenter randomized controlled trial was to com-
pare invasive and conservative strategies in the very elderly with NSTE-ACS.
Methods: We randomly assigned patients  80 years of age with NSTE-ACS to an invasive strategy
with coronary angiography and optimal medical treatment or a conservative strategy with only opti-
mal medical treatment. The primary outcome was the combined endpoint of major adverse cardiac
and cerebrovascular events (MACCE). Sample size was powered for a 50% reduction of event rate in
MACCE with an invasive strategy. We used intention-to-treat analysis.
Results: Altogether, 186 patients were included between 2009 and 2017. The study was terminated
prematurely due to slow enrollment. At 12-month follow-up, the primary outcome occurred in 31
(33.3%) of the invasive treatment group and 34 (36.6%) of the conservative treatment group, with a
hazard ratio (HR) of 0.90 (95% CI 0.55–1.46; p¼ 0.66) for the invasive group relative to the conservative
group. The corresponding HR value for urgent revascularization was 0.29 (95% CI 0.10–0.85; p¼ 0.02),
0.56 (95% CI 0.27–1.18; p¼ 0.13) for myocardial infarction, 0.70 (95% CI 0.31–1.58; p¼ 0.40) for all-
cause mortality, 1.35 (95% CI 0.23–7.98; p¼ 0.74) for stroke, and 1.62 (95% CI 0.67–3.90; p¼ 0.28) for
recurrent hospitalization for cardiac reasons.
Conclusion: In the very elderly with NSTE-ACS, we did not find any significant difference in MACCE
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The prevalence of coronary heart disease increases with
increasing age [1], and the elderly constitute a high propor-
tion of patients that present with non-ST elevation acute
coronary syndrome (NSTE-ACS) [2,3]. Several randomized
controlled trials (RCTs) have shown that invasive treatment
with percutaneous coronary intervention (PCI) together
with optimal medical treatment is superior to optimal med-
ical treatment alone in patients with NSTE-ACS [4–7]. An
invasive treatment strategy is therefore the standard of care
in NSTE-ACS. However, elderly patients have been under-
represented in many RCT studies [8,9] and are less likely to
receive evidence-based therapies [10,11]. Current guidelines
from European Society of Cardiology recommend elderly
patients to be considered for invasive treatment with PCI,
and guidelines of the American Heart Association/American
College of Cardiology for the management of patients with-
out ST elevation (NSTE-ACS) recommend invasive treat-
ment and revascularization if appropriate in patients who
are >75 years [12,13]. Few studies have suggested that PCI
may have a beneficial effect on survival of the elderly with
NSTE-ACS [10,11,14,15]. A recent RCT [16] showed that
invasive treatment was superior to conservative treatment in
reduction of myocardial infarction and need for urgent
revascularization, but no significant difference was found in
mortality. A recent meta-analysis [17] highlighted the need
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for further RCTs to determine the effect of invasive treat-
ment in elderly patients.
In the present study, our primary aim was to compare an
invasive treatment strategy with conservative treatment in
the very elderly with NSTE-ACS, in terms of major adverse
cardiac and cerebrovascular events (MACCE). Secondary
aims were to compare bleeding events and angina class
between invasive and conservative treatment strategies at
follow-up. Our hypothesis was that invasive treatment
would be superior to conservative treatment in reducing the




The study was an open-label, randomized, controlled multi-
center trial involving patients 80 years with NSTE-ACS.
The trial had two parallel treatment arms: an invasive group
and a conservative group. Patients were recruited from three
different hospitals in the southwestern Sweden. For details
of patient allocation and recruitment time for each hospital,
see Supplementary Table 1. The study protocol has been
published [18].
Recruitment
The study nurse screened patients who were eligible for
inclusion. The inclusion criteria were: (1) 80 years; (2)
NSTE-ACS with ischemic symptoms (chest pain) lasting
over 10min in the previous 72 h; and (3) ischemic ST-seg-
ment depression 1mm and/or elevated troponin I, tropo-
nin T, or CK-MB. The exclusion criteria were: (1) PCI
within 30 days prior to randomization; (2) ongoing active
internal bleeding; (3) ST-segment elevation of 1mm in
two contiguous leads on ECG; (4) enrolled in another study
that has not completed follow-up; (5) known allergy to
aspirin or P2Y12 antagonists; (5) severe dementia; (6)
expected limited 1-year survival due to other diseases; and/
or (7) unwillingness to participate or expected problems
with compliance. All patients signed an informed consent
document before randomization.
Randomization and procedures
After patients had given informed consent, they were
randomized with a permuted block randomization 1:1 to
one of two treatment strategies, using sealed envelopes. The
invasive treatment included coronary angiography and, if
appropriate, revascularization with PCI or coronary artery
bypass grafting (CABG), and optimal medical treatment
[12]. The conservative treatment strategy included optimal
medical treatment without coronary angiography. Patients
in the conservative treatment group were to undergo coron-
ary angiography if refractory chest pain, hemodynamic
instability, heart failure, or life-threatening cardiac arrhyth-
mias and revascularized if appropriate. After inclusion,
evaluation of the degree of frailty was assessed at bedside
according to the Canadian Study of Health and Aging clin-
ical frailty scale [19]. The severity of angina was graded by
the study nurse by telephone. All patients were assessed for
adverse events and serious adverse events by telephone and
from medical records.
Outcome
The primary outcome was the first event of the combined
endpoint of MACCE within 12months. MACCE was a com-
bination of the following: myocardial infarction, urgent revas-
cularization, all-cause mortality, stroke, and recurrent
hospitalization for cardiac reasons. The secondary outcomes
included: MACCE within 1-month, all-cause mortality, myo-
cardial infarction, death and/or myocardial infarction within
12months, major and minor bleeding within 1-month, and
angina class, assessed at 1-month and 12-month follow-up
using the Canadian cardiovascular society (CCS) scale.
Definitions
Recurrent hospitalization for cardiac reasons was defined as
due to new onset atrial fibrillation or heart failure. Stroke
was defined as cerebral ischemic events including transitory
ischemic attack. Recurrent intervention was any unplanned
revascularization after the index hospitalization. Major bleed-
ing was defined as either intracranial bleeding, a decrease in
haemoglobin level of more than 50 g/L, or bleeding requiring
surgery. Minor bleeding was defined as a decrease in haemo-
globin of more than 30 g/L but less than 50 g/L, spontaneous
gross haematuria, haematemesis, haematoma, or pseudoa-
neurysm requiring treatment (other than surgery) [20].
Sample size
Based on a sub-study in the TACTICS-TIMI 18 trial [15], we
expected a MACCE rate of 40% within 12months in those
allocated to conservative treatment. To detect a reduction in
MACCE rate of 50%, with a power of 80% and a significance
level of 0.05, 82 individuals were required in each group. To
ensure enough patients for evaluation, our intention was to
include a total of 100 individuals in each group.
Statistical analysis
The main analysis was intention-to-treat. However, we per-
formed also per-protocol analysis of the primary endpoint
(MACCE) for details see Supplementary table 4.
The (absolute) standardized difference, was used to assess
balance between the two treatment groups regarding base-
line characteristics.
For MACCE during 12-month follow-up, Kaplan-Meier
curves regarding survival free from MACCE for the two
treatment groups were constructed and compared using the
log-rank test. In the tables and results, outcome rates at 1
and 12months are given as percentages calculated as 100
minus Kaplan-Meier estimates and Cox proportional
2 G. HIRLEKAR ET AL.
hazards regression was used for calculation of hazard ratios
with corresponding 95% confidence intervals, except for
angina class at 1 and 12months, where crude percentages
are given and the groups were compared using Mann-
Whitney U-test.
All tests were two-sided and p-values less than 0.05 were
considered statistically significant. No interim analysis was
performed. All analyses were performed using SAS for
Windows version 9.4.
Ethics
The local ethics committee in Gothenburg approved
the study protocol on 28 April 2009 (registration number
157-09). The study was registered at ClinicalTrials.gov
(NCT02126202).
Results
From September 2009 to September 2017, 186 patients aged
80 years with NSTE-ACS were randomly assigned at three
centers to invasive strategy (93 patients) or conservative
strategy (93 patients) (Figure 1). The trial was terminated
prematurely due to slow enrollment. During follow-up, five
patients withdrew informed consent.
Baseline characteristics
Baseline characteristics of study patients are presented in
Table 1. Although patients were randomized, the groups
were rather imbalanced in the following aspects: patients in
the conservative group generally had a higher pulse, more
often renal dysfunction, and more often atrial fibrillation. In
the invasive group, 21% were considered frail compared to
13% in the conservative group.
During index hospitalization, 89 patients in the invasive
treatment group had a coronary angiography performed,
followed by 57 PCIs and 1 CABG . Of those treated with
PCI, 33% were completely revascularized. Drug-eluting
stents (DES) were used in 44% of all PCIs. In the conserva-
tive treatment group, four patients had coronary angiog-
raphy performed, followed by 3 PCIs and 1 CABG. Of the
invasive treatment patients, 91 were discharged alive
opposed to 92 in the conservative group. Medications at dis-
charge were similar in the two groups.
Primary outcome
During 12-month follow-up, MACCE occurred in 31 patients
in the invasive group and in 34 in the conservative group
(HR ¼ 0.90 (95% CI 0.55–1.46; p¼ 0.66)) (Table 2 and
Figure 2). Accordingly, the HR was 0.56 (95% CI 0.27–1.18;
p¼ 0.13) in the invasive group relative to the conservative
group regarding myocardial infarction, 0.29 (95% CI
0.10–0.85; p¼ 0.02) regarding need of urgent revasculariza-
tion, 0.70 (95% CI 0.31–1.58, p¼ 0.40) regarding all-cause
mortality, 1.35 (95% CI 0.23–7.98; p¼ 0.74) regarding stroke,
and 1.62 (95% CI 0.67–3.90; p¼ 0.28) regarding recurrent
hospitalization for cardiac reasons, for details see Table 2. Six
patients died from a cardiovascular cause in the invasive
group and 11 in the conservative group. Analysis of primary
outcome excluding recurrent hospitalization due to cardiac
reasons was HR 0.72 (95% CI 0.41–1.22; p¼ 0.22) with 24
(26.7%) events in invasive group and 31 (34.4%) in the con-
servative group. Primary outcome excluding recurrent hospi-
talization and non-cardiovascular death was HR 0.65 (95% CI
0.37–1.14; p¼ 0.13) (for details, see Supplementary Table 2).
Secondary outcome and bleeding
There was no significant difference in any secondary out-
come between the two treatment groups. None of the
patients had a major bleeding within 1month, but four had
a minor bleeding in the invasive group and two had a
minor bleeding in the conservative group (Table 2).
Figure 1. Trial profile.
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Age 84 (81,90) 84 (81,89) 0.10
Male sex 47 [50.5%] 55 [59.1%] 0.17
Weight, kg (1/5) 73 (59,94) 73 (56,94) 0.02
Systolic blood pressure, mmHg 142 (120,174) 142 (119,180) 0.05
Diastolic blood pressure, mmHg 79 (64,98) 80 (68,100) 0.18
Heart rate, beats/min (0/1) 69 (56,92) 80 (55,99) 0.45
Renal dysfunction (eGFR <60) 59 [63.4%] 70 [75.3%] 0.26
Elevated troponin T or I or CK-MB  92 [98.8%] 88 [94.6%] 0.25
Previous medical history:
Angina pectoris (1/1) 36 [39.1%] 41 [44.6%] 0.11
Myocardial infarction (2/0) 29 [31.9%] 35 [37.6%] 0.12
PCI (1/0) 15 [16.3%] 16 [17.2%] 0.02
CABG 19 [20.4%] 14 [15.1%] 0.14
Hypertension 55 [59.1%] 59 [63.4%] 0.09
Diabetes mellitus 16 [17.2%] 20 [21.5%] 0.11
Hyperlipidemia 21 [22.6%] 16 [17.2%] 0.13
Heart failure 10 [10.8%] 8 [8.6%] 0.07
Peripheral artery disease 3 [3.2%] 6 [6.5%] 0.15
Stroke 10 [10.8%] 15 [16.1%] 0.16
Atrial fibrillation (1/1) 10 [10.9%] 17 [18.5%] 0.22
Medication at inclusion:
Beta blocker 37 [39.8%] 48 [51.6%] 0.24
ACE inhibitor (1/0) 23 [25.0%] 26 [28.0%] 0.07
ARB inhibitor (1/0) 18 [19.6%] 24 [25.8%] 0.15
Calcium channel blocker (1/0) 23 [25.0%] 20 [21.5%] 0.08
Long-acting nitrates 25 [26.9%] 20 [21.5%] 0.13
Rapidly acting nitrates 26 [28.0%] 30 [32.3%] 0.09
Aspirin 51 [54.8%] 50 [53.8%] 0.02
Clopidogrel (0/2) 8 [8.6%] 7 [7.7%] 0.03
Warfarin 7 [7.5%] 12 [12.9%] 0.18
Statins (1/0) 30 [32.6%] 37 [39.8%] 0.15
Diuretics (0/1) 33 [35.5%] 39 [42.4%] 0.14
Digitalis 5 [5.4%] 3 [3.2%] 0.11
Oral diabetic treatment 11 [11.8%] 12 [12.9%] 0.03
Insulin (1/0) 6 [6.5%] 5 [5.4%] 0.05
Frailty scale: (12/11) 0.10
1 5 [6.2%] 4 [4.9%]
2 20 [24.7%] 21 [25.6%]
3 26 [32.1%] 32 [39.0%]
4 13 [16.0%] 14 [17.1%]
5 12 [14.8%] 9 [11.0%]
6 5 [6.2%] 2 [2.4%]
7 0 [0.0%] 0 [0.0%]
5–7 17 [21.0%] 11 [13.4%] 0.20
Smoking status: (4/5)
Present 2 [2.2%] 3 [3.4%] 0.07
Previous 33 [37.1%] 39 [44.3%] 0.15
Ejection fraction (8/19) 55 (35,60) 54 (35,60) 0.02
ECG at admission:
ST depression (4/5) 35 [39.3%] 39 [44.3%] 0.10
LBBB (6/3) 6 [6.9%] 12 [13.3%] 0.21
During index hospitalization:
Coronary angiography 89 [95.7%] 4 [4.3%]
PCI 57 [61.3%] 3 [3.2%]
CABG 1 [1.1%] 1 [1.1%]
LM 16 [18%] 2 [50%]
3-vessel disease 20 [22%] 1 [25%]
2-vessel disease 21 [24%] 0
1- vessel disease 19 [21%] 1 [25%]
No significant stenosis 13 [15%] 0
Discharged alive n¼ 91 n¼ 92
Medication at discharge:
Beta blocker (1/0) 79 [87.8%] 83 [90.2%] 0.08
ACE inhibitor (2/0) 40 [44.9%] 43 [46.7%] 0.03
ARB inhibitor (2/0) 17 [19.1%] 24 [26.1%] 0.17
Calcium channel blocker (3/0) 16 [18.2%] 21 [22.8%] 0.12
Long-acting nitrates (4/0) 32 [36.8%] 44 [47.8%] 0.22
Rapidly acting nitrates (3/1) 65 [73.9%] 72 [79.1%] 0.12
Aspirin (1/0) 82 [91.1%] 82 [89.1%] 0.07
P2Y12 inhibitor (1/0) 80 [88.9%] 81 [88.0%] 0.03
Warfarin (4/2) 9 [10.3%] 15 [16.7%] 0.19
Statins (2/1) 71 [79.8%] 74 [81.3%] 0.04
Diuretics (1/1) 34 [37.8%] 42 [46.2%] 0.17
Digitalis (2/1) 5 [5.6%] 3 [3.3%] 0.11
Oral diabetes treatment (2/0) 8 [9.0%] 13 [14.1%] 0.16
Insulin (2/0) 6 [6.7%] 5 [5.4%] 0.05
LBBB: left bundle branch block. The data in the two main columns are median (10th, 90th percentile) or n [per cent].Number of patients for whom information was missing in the two groups, respectively.  Elevated biochemical marker more than three times the normal
level. #(Absolute) standardized difference.
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Angina during follow-up
There was no difference in angina severity between the two
treatment groups, neither at 1-month nor at 12-months (for
details, see Supplementary Table 3).
Per-protocol analysis
The per protocol analysis gave results similar to the inten-
tion-to-treat analysis, namely an HR of 0.97 (95% CI
0.58–1.62; p¼ 0.92) (for details, see Supplementary Table 4).
Discussion
The main finding was that there was no statistically signifi-
cant difference in MACCE between invasive treatment and
conservative treatment in the very elderly with NSTE-ACS
over 12months. In addition, we found no significant
difference regarding all-cause mortality or severity of angina
during follow-up. Although our results support current evi-
dence that an invasive treatment strategy reduces the need
for revascularization, there was no benefit regard-
ing mortality.
Previous randomized clinical trials focusing on the eld-
erly have compared invasive and conservative treatment
strategies in patients with NSTE-ACS and shown conflicting
results. The Italian ACS Elderly trial [21] involving patients
75 years did not show any outcome benefit in elderly
NSTE-ACS patients treated invasively, but a subgroup ana-
lysis did show reduced mortality in those with high tropo-
nin levels treated with PCI. In the subgroup analysis in the
TACTIC-TIMI 18 trial [15] with patients aged >75 years, an
early invasive treatment strategy reduced the composite end-
point of death and MI at 6months. The After Eighty trial
[16] showed a reduction in the combined endpoint of myo-
cardial infarction, need for urgent revascularization, stroke,
Figure 2. Kaplan-Meier curves of survival free from the primary combined outcome of MACCE at 12-month follow-up. The primary combined outcome was a com-
posite of myocardial infarction, urgent revascularization, all-cause mortality, stroke, and recurrent hospitalization due to cardiac reason.




group (n¼ 93) HR (95% CI)# p-value
Primary outcome (MACCE) 31 (34.4%) 34 (37.4%) 0.90 (0.55–1.46) 0.66
Components of MACCE:
Myocardial infarction 11 (12.9%) 19 (22.3%) 0.56 (0.27–1.18) 0.13
Urgent revascularization 4 (4.6%) 14 (16.5%) 0.29 (0.10–0.85) 0.02
All-cause mortality 10 (11.0%) 14 (15.2%) 0.70 (0.31–1.58) 0.40
Stroke 3 (3.7%) 2 (2.3%) 1.35 (0.23–7.98) 0.74
Recurrent hospitalization due to new AF or HF 13 (15.2%) 8 (9.4%) 1.62 (0.67–3.90) 0.28
Secondary outcome and bleeding
Any MACCE within 1 month 11 (11.9%) 15 (16.2%) 0.72 (0.33–1.56) 0.40
All-cause mortality within 12 months 10 (11.0%) 14 (15.2%) 0.70 (0.31–1.58) 0.40
Myocardial infarction within 12 months 11 (12.9%) 19 (22.3%) 0.56 (0.27–1.18) 0.13
Death and/or myocardial infarction within 12 months 20 (22.2%) 26 (28.9%) 0.74 (0.41–1.33) 0.31
Major bleeding within 1 month 0 (0.0%) 0 (0.0%) 1.00
Minor bleeding within 1 month 4 (4.4%) 2 (2.2%) 1.81 (0.34–9.61) 0.49
AF: atrial fibrillation; HF: heart failure. The data in the two main columns are numbers (Kaplan-Meier estimate in per cent).
#Hazard ratio for invasive treatment group in relation to conservative treatment group, with corresponding 95% confidence interval. Patients could experience
more than one of the components (although only the first to occur was included in MACCE).
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and death, with an invasive treatment strategy being com-
pared to a conservative one. In the present study, we had a
different combined endpoint and a shorter follow-up com-
pared to the After Eighty trial. Additionally, our analysis of
primary outcome excluding recurrent hospitalization and
non-cardiovascular death did not show any significant dif-
ference between groups.
Neither all-cause mortality nor cardiovascular death in
the present study differed significantly between the two
treatment strategies. This is in agreement with previous
RCTs. In our study, 12-month mortality was similar to that
in the Italian ACS Elderly trial and the After Eighty trial.
The patients in our study had a similar comorbidity to that
in these two studies. Furthermore, our cohort had low
frailty, which has previously been found to be independently
associated with 1-year mortality [22].
Our finding of no difference in angina class between the
treatment strategies, conflicts with other studies [23], which
have found greater reduction in angina with invasive treat-
ment. One possible explanation is that the patients in our
conservative treatment group received more intensive anti-
angina treatment medication than those in the invasive
treatment group.
Previous studies have shown that elderly patients are
more liable to major bleeding after invasive treatment than
with medical treatment, but this difference was not observed
in a recent meta-analysis [17]. Thus, the present trial is
more in line with recent publications. In Sweden, there is a
high proportion of radial access in coronary angiography
and a low use of Gp IIb/IIIa receptor inhibitors, which
could possibly explain the low rate of bleeding events [24].
In summary, there was no statistically significant differ-
ence in MACCE between invasive treatment and conserva-
tive treatment in the very elderly with NSTE-ACS over
12months. As our cohort was quite healthy it is uncertain
that the results can be extrapolated to the more frail patients
with several comorbidities that we encounter in clinical
practice [25].
Strengths and limitations
The strength of this study was the use of randomization for
treatment allocation, thus limiting residual confounding and
confounding by indication. However, there were several lim-
itations. Firstly, in spite of the random allocation to the two
treatment strategies, there were imbalances between the
groups regarding certain baseline characteristics. At
12months the relative risk reduction in the primary end-
point was 10% between the invasive group and conservative
group. The study was powered to detect a 50% reduction in
the primary endpoint rate in the invasive group which was
optimistic, i.e. the study was underpowered to show any
benefit when the difference in event rate was so low.
There were a few crossover patients between the two
treatment groups during index hospitalization. Moreover,
data on eligibility for inclusion were missing from two study
sites, so we were unable to include accurate information
about all screened patients but we assume that the
proportion of enrolled patients out of possible candidates
was extremely low.
Furthermore, the slow patient enrollment rate caused a
long recruitment period causing the study to terminate pre-
maturely which is a major limitation. However, the number
of randomized patients was not far from the number of
required patients according to the sample size calculation.
The problem with a slow enrollment has been observed in
other studies [21,26] and reflects a problem with the recruit-
ment of very elderly patients in RCTs, especially when the
investigated intervention is established in younger patients.
These problems must become well known to scientists who
plan to start similar types of studies. We need to learn more
about the difficulties and ethical problems associated with
the inclusion of the very elderly in randomized clinical trials
and about their preferences in the acute phase of a cardio-
vascular disease.
The long recruitment period became a confounder par-
ticularly due to the development of treatment in both the
medical and invasive strategy group such as secondary pre-
vention, more usage of DES and complete revascularization
that may have influenced the outcome. Thereby the applica-
tion of the results to current practice are limited. Finally,
different study sites including patients at different rates may
have influenced patient selection and thereby the generaliz-
ability of the results.
Conclusion
In the very elderly with NSTE-ACS, we did not find any sig-
nificant difference in MACCE between the invasive and
conservative treatment groups at 12-month follow-up, pos-
sibly due to small sample size.
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